
    
      Subjects will enter this open-label extension study after completing the placebo-controlled,
      double-blind study Res-5-0002 (NCT00538434). The end of study visit for Res-05-0002 will
      serve as the screening visit for this trial.

      All subjects will receive reslizumab and be followed by their principal investigators in an
      unblinded fashion. Visits and administration of reslizumab will be monthly.
    
  